Fiche publication
Date publication
octobre 2025
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
,
Pr ROSSI Cédric
Tous les auteurs :
Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquieres H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Obéric L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud VI
Lien Pubmed
Résumé
Early detection of ultra-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to cancer patient biofluids has emerged as a novel Omics that could provide important information to better stratify cancer patients. We performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized DLBCL patients treated by R-CHOP (from the phase 3 REMARC trial, #NCT01122472). Remarkably, we identified a combination of three circulating metabolites linked to lipid metabolism (named the "NMR score") that significantly impacted on overall survival (OS) (p < 0.0001) and progression-free survival (PFS) (p = 0.0003). The optimal cut off for each metabolite was determined using X-Tile and confirmed by a training validation method. Combining 2-amino-butyrate, 3-hydroxy-butyrate and LDL-1 lipoprotein yielded three risk groups with low (0-1), intermediate (2-3) and high risk (4-5) patients. GCB/non-GCB profile along with Bcl2 and Myc expression did not correlate with NMR score survival. In conclusion, we revealed that a combination of three circulating metabolites linked to lipid metabolism is a feature that capture DLBCL patient heterogeneity. This NMR score appeared promising for DLBCL risk stratification, even among responder patients after R-CHOP treatment.
Référence
Blood Adv. 2025 10 7;:
